Journal Article

DZNE-2026-00888

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png APOE and genetic risk variants influence Alzheimer's disease onset in carriers of an extra copy of APP, with and without Down syndrome.

Groeneveld, J. ; Perlaza, D. ; Olivé, C. ; Grangeon, L. ; Tesi, N. ; Nicolas, A. ; Jiang, C. ; de Rojas, I. ; Wallon, D. ; Rousseau, S. ; Rovira, M. ; de Asúa, D. R. ; Moldenhauer, F. ; Mu, R. ; Cassinari, K. ; Zarea, A. ; Escabias, J. A. ; Lambert, J.-C. ; Pijnenburg, Y. A. L. ; Hulsman, M. ; Vijverberg, E. G. B. ; Levin, J.DZNE* ; Jucker, M.DZNE* ; McDade, E. ; Fortea, J. ; Holstege, H. ; Duits, F. H. ; Vermunt, L. ; Patel, M. ; Johnson, M. ; Renton, A. E. ; Goate, A. M. ; Cruchaga, C. ; Pottier, C. ; Fernandez, M. V. ; Belbin, O. ; Nicolas, G. ; Dols-Icardo, O. ; van der Lee, S. J. ; Network, D. I. A. (Collaboration Author)

2026
Wiley Hoboken, NJ

This record in other databases:    

Please use a persistent id in citations: doi:10.1002/alz.71738

Abstract: An extra copy of the amyloid precursor protein (APP) gene causes autosomal dominant Alzheimer's disease (AD) and AD in Down syndrome (DS), but the factors underlying variability in age at onset (AAO) remain unclear. We investigated whether sporadic AD risk variants modify AAO.We analyzed clinical and genetic data from 100 APP duplication (APPdup) carriers and 957 individuals with DS. Cox models assessed associations of apolipoprotein E (APOE) ε2 and ε4 and the AD genetic risk score (AD-GRS; excluding APOE and chromosome 21 variants) with AAO.Mean AAO was earlier in APPdup than DS (51 ± 7 vs. 53 ± 6 years; P = 0.0005). APOE ε2 delayed onset (hazard ratio [HR] = 0.47, P < 0.0001), whereas APOE ε4 (HR = 1.5, P = 0.0003) and higher AD-GRS (HR = 1.3 per standard deviation, P < 0.0001) accelerated onset. Predicted median AAO differed by 10 years between lowest and highest genetic risk.Sporadic AD genetic risk factors are important modifiers of AAO in APPdup and DS, explaining part of the marked variability in onset.

Keyword(s): Humans (MeSH) ; Down Syndrome: genetics (MeSH) ; Down Syndrome: complications (MeSH) ; Alzheimer Disease: genetics (MeSH) ; Alzheimer Disease: epidemiology (MeSH) ; Alzheimer Disease: complications (MeSH) ; Amyloid beta-Protein Precursor: genetics (MeSH) ; Female (MeSH) ; Age of Onset (MeSH) ; Male (MeSH) ; Middle Aged (MeSH) ; Genetic Predisposition to Disease (MeSH) ; Apolipoproteins E: genetics (MeSH) ; Heterozygote (MeSH) ; Genetic Risk Score (MeSH) ; Risk Factors (MeSH) ; Apolipoprotein E4: genetics (MeSH) ; Alzheimer's disease ; Down syndrome ; Down syndrome‐associated Alzheimer's disease ; amyloid precursor protein duplication ; apolipoprotein E ; autosomal dominant Alzheimer's disease ; disease onset ; polygenic risk score ; Amyloid beta-Protein Precursor ; Apolipoproteins E ; APP protein, human ; Apolipoprotein E4

---

Contributing Institute(s):

1. Clinical Neurodegeneration (AG Levin)
2. Clinical Research (Munich) (Clinical Research (Munich))
3. Cell Biology of Neurological Diseases (AG Jucker)

Research Program(s):

1. 353 - Clinical and Health Care Research (POF4-353) (POF4-353)
2. 352 - Disease Mechanisms (POF4-352) (POF4-352)

Appears in the scientific report 2026

---

Database coverage:
; ; ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; DEAL Wiley ; Essential Science Indicators ; IF >= 10 ; JCR ; PubMed Central ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---